Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-Sequence 2: Neoadjuvant Chemo + Anti-angiogenesis + Immunotherapy in Gastric Cancer
NCT06371586Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Mar 2024
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of paclitaxel, tegafur, oxaliplatin, bevacizumab, PD-1 Monoclonal Antibody in diffuse gastric cancer (DGC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Mar 2024; status: recruiting.
02
Drugs
paclitaxeltegafuroxaliplatinbevacizumabPD-1 Monoclonal Antibody
03
Conditions
diffuse gastric cancer (DGC)
Beyond the preview
Go deeper on NCT06371586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06371586.